By Deanna Mudie, Ph.D., Principal Scientist, R&D, Lonza
The prevalence of active compounds with low aqueous solubility exceeds 70% in drug pipelines, preventing development of many compounds as effective medicines. Spray-dried amorphous solid dispersions (ASDs) are effective in increasing drug solubility and enhancing the bioavailability of such compounds, but the amount of excipients in ASDs may be too large to attain the high drug loadings needed for some therapies. Lonza has developed a novel platform that addresses this challenge, reducing tablet mass by nearly half and maintaining high drug loading, physical stability, and supersaturation. A case study is presented.